Status:
COMPLETED
Cellular Immunity and Renal Cell Cancer
Lead Sponsor:
Clinical Hospital Center Rijeka
Conditions:
NK Cell Mediated Immunity
NK Cell Cytokine Production
Eligibility:
All Genders
18+ years
Brief Summary
Renal cell cancer (RCC) is one of the most important urogenital tumors because of it's high mortality and increasing incidence. RCC, which accounts about 3% of all malignant tumors in the adults, is t...
Detailed Description
Cellular immunity will be investigated in the two group of patients: operated patients with RCC and healthy volunteers. In the study investigators will determine patterns of aggregation of tumor infi...
Eligibility Criteria
Inclusion
- RCC (renal cell cancer) patients
- operated patients
- both gender
- older than 18 years
- written informed consent
Exclusion
- age younger of 18
- patients with metastatic disease
- patients receiving antibiotics 6 weeks before operation
- patients regularly treated with corticosteroids or immunosuppressive drugs
- transplanted patients
- patients with autoimmune diseases and/or vasculitis
Key Trial Info
Start Date :
May 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 26 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04377113
Start Date
May 24 2020
End Date
July 26 2021
Last Update
September 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Hospital Center Rijeka
Rijeka, Croatia, 51 000